Prostate Cancer: Update on Early Detection and New Biomarkers
Grubb, R.L.
Missouri Medicine 115(2): 132-134
2018
ISSN/ISBN: 0026-6620 PMID: 30228704 Document Number: 696807
Screening and early treatment of prostate cancer (PCa) has recently come under scrutiny due to the rates of overdiagnosis of low risk cancer. Randomized trials, including ERSPC and PLCO, have informed our understanding of the survival benefit provided by systematic PCa screening with serum prostate-specific antigen (PSA). To reduce the number of patients diagnosed with indolent disease, new adjuvant risk stratification tests have become available.